Share

January 2019; 6 (1) Editor's CornerOpen Access

N2 year in review and message from the editor to our reviewers

Josep Dalmau, Dennis L. Kolson, Friedemann Paul, Scott S. Zamvil
First published December 19, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000525
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
315

Share

Article Information

vol. 6 no. 1 e525
DOI: 
https://doi.org/10.1212/NXI.0000000000000525
PubMed: 
30637299
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published December 19, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Josep Dalmau, MD, PhD,
    2. Dennis L. Kolson, MD, PhD,
    3. Friedemann Paul, MD and
    4. Scott S. Zamvil, MD, PhD
  1. Josep Dalmau, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate

    Patents:

    1. Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advance Medical

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. -NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun

    Royalty Payments, Technology or Inventions:

    1. Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Dennis L. Kolson, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1R01 MH104134-01 (Kolson) 5/1/2014 ? 4/30/19 NIH/NIMH Oxidative stress, immune activation and therapeutic targeting in HAND The goals are to determine the association between brain regional heme oxygenase deficiency and neurocognitive impairment in HIV infected individuals, and to determine whether the simian immunodeficiency virus (SIV) primate model for neuroAIDS can be used to assess heme oxygenase- targeted therapies. Role: (PI) Overlap: There is no scientific or budgetary overlap 1R01 MH111389-01 (Kolson) 8/18/16 ? 5/31/21 NIH/NIMH Regulation of heme oxygenase in HIV/HAND pathogenesis The goals are to define the potential neuropathogenic role for a common heme oxygenase-1 promoter dinucleotide (GT)n repeat in the dysregulation of heme oxygenase-1 expression in HIV-infected individuals and determine the associated mechanisms of blood-brain barrier dysfunction. Role: (PI) Overlap: There is no scientific or budgetary overlap 1R01NS101156-01A1: (Talos) 1/01/2018-12/31/2023 NIH/NINDS The role of oxidative stress and inflammation in epileptogenesis The goals are to investigate specific blood and brain tissue biomarkers of inflammation and oxidative stress in mouse models of epileptogenesis, and to test novel neuroprotective strategies to prevent the development of chronic epilepsy and/or its neuropsychiatric co-morbidities. Role: Co-I Overlap: There is no scientific or budgetary overlap 1P30MH097488-01A1: (Evans) 6/03/13 - 05/31/18 NIH/NIMH Penn mental health AIDS research center This Center will specifically focus on the combination of mental illness and HIV/AIDS and related comorbidities to develop innovative, integrated treatments to optimize psychiatric, behavioral, and medical outcomes and to achieve a better understanding of the biological, psychological, and behavioral mechanisms underlying these combined illnesses and treatments. Dr. Kolson serves as consultant and scientific advisor for studies of HIV- associated neurocogntive disorders (HAND) and their relationship to psychiatric illnesses. Role: Co-I Overlap: There is no scientific or budgetary overlap

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Friedemann Paul, MD and
    4. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Scott S. Zamvil, MD, PhD
    5. Scientific Advisory Boards:

    1. Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. He is a member of the Clinical Advisory Board for the Myelin Repair Foundation.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Neuroimmunology and Neuroinflammation, Deputy Editor, 2014-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.

    Speakers' Bureaus:

    1. Advanced Health Media, 2009-present Biogen, 2009-present

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen (2) Teva

    Research Support, Government Entities:

    1. NIH RO1 NS092835-01

    Research Support, Academic Entities:

    1. NMSS RG 1701-26628 NMSS RG 1801-29861

    Research Support, Foundations and Societies:

    1. Alexander M. and June L. Maisin Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the ICREA-IDIBAPS, Hospital Clínic (J.D.), University of Barcelona, Spain; the University of Pennsylvania (J.D, D.L.K.), Philadelphia, PA; the Charite University Hospital (F.P.), Berlin, Germany; and the Department of Neurology (S.S.Z.), University of California, San Francisco, CA.
View Full Text

Article usage

Article usage: December 2018 to January 2020

AbstractFullPdfSource
Dec 2018031518Highwire
Jan 2019431944Highwire
Feb 2019611415Highwire
Mar 2019020624Highwire
Apr 2019329413Highwire
May 2019453882Highwire
Jun 20195112051Highwire
Jul 201936549Highwire
Aug 2019279812Highwire
Sep 201915869Highwire
Oct 2019357613Highwire
Nov 2019339014Highwire
Dec 2019032610Highwire
Jan 202001041Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me

Advertisement